ACON Aclarion, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1635077 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY46.0%
TTM net income YoY-37.9%
TTM EPS YoY99.7%
Revenue 3-yr CAGR5.4%
Net income 3-yr CAGR—
Margins
Gross margin29.1%
Operating margin-10,789.2%
Net margin-10,260.0%
FCF margin—
EBITDA margin-10,662.3%
Returns
ROE-74.1%
ROA-69.7%
ROIC (approx.)-958.9%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets6.5%
Debt / equity0.00x
Current ratio14.17x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.88x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $33,733 | $25,208 | $21,140 | $18,479 | $18,942 | $19,319 | $18,991 | $10,232 |
| Cost of revenue | $18,937 | $16,911 | $17,390 | $16,688 | $14,556 | $14,179 | $23,479 | $20,556 |
| Gross profit | $14,796 | $8,297 | $3,750 | $1,791 | $4,386 | $5,140 | -$4,488 | -$10,324 |
| R&D expense | $371,511 | $297,070 | $315,417 | $263,130 | $302,037 | $270,434 | $198,190 | $251,826 |
| SG&A expense | $1.64M | $1.73M | $1.77M | $1.11M | $900,904 | $1.13M | $986,663 | $1.21M |
| Operating income | -$2.75M | -$2.90M | -$2.99M | -$1.99M | -$1.83M | -$1.74M | -$1.49M | -$1.81M |
| Pretax income | -$2.62M | -$2.75M | -$2.85M | -$1.89M | -$1.71M | -$1.60M | -$2.04M | -$1.99M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$2.62M | -$2.75M | -$2.85M | -$1.89M | -$1.71M | -$1.60M | -$2.04M | -$1.99M |
| EBITDA | -$2.75M | -$2.90M | -$2.93M | -$1.93M | -$1.83M | -$1.74M | -$1.44M | -$1.75M |
| EPS (basic) | -0.94 | -1.12 | -1.34 | — | -2.93 | -2.75 | -9.32 | — |
| EPS (diluted) | -0.94 | -1.12 | -1.34 | — | -2.93 | -2.75 | -9.32 | — |
| Weighted avg. shares (diluted) | 2.78M | 2.46M | 2.13M | — | 582,371 | 582,371 | 219,366 | — |
| Banking | ||||||||
| Deposits | — | — | — | — | — | — | $1.39M | $463,661 |
| Balance sheet | ||||||||
| Cash & equivalents | $14.19M | $16.29M | $19.00M | $12.02M | $11.37M | $12.85M | $14.76M | $463,661 |
| Receivables | $33,243 | $28,172 | $40,583 | $29,680 | $32,018 | $20,920 | $19,172 | $18,326 |
| Current assets | $14.58M | $16.79M | $19.38M | $12.40M | $11.90M | $13.44M | $15.16M | $824,279 |
| PP&E, net | $21,786 | $23,233 | $22,872 | $24,169 | $13,164 | $6,461 | $5,093 | $5,499 |
| Intangibles | $1.23M | $1.22M | $1.24M | $1.25M | $1.28M | $1.31M | $1.32M | $1.29M |
| Total assets | $15.83M | $18.04M | $20.64M | $13.67M | $13.20M | $14.75M | $16.48M | $2.12M |
| Current liabilities | $1.03M | $1.04M | $986,208 | $837,287 | $699,747 | $564,422 | $699,032 | $1.15M |
| Total liabilities | $1.03M | $1.04M | $986,208 | $837,287 | $699,747 | $564,422 | $699,032 | $1.15M |
| Shareholders' equity | $14.81M | $17.00M | $19.65M | $12.84M | $12.50M | $14.19M | $15.78M | $970,057 |
| Shares outstanding | 2.88M | 2.46M | 2.44M | 854,371 | 582,371 | 582,371 | 582,338 | 1,370 |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.02M | -$2.66M | -$2.64M | -$1.63M | -$1.16M | -$1.87M | -$2.51M | -$922,861 |
| Capital expenditure | $0 | — | — | $13,726 | $7,321 | — | — | $5,115 |
| Free cash flow | -$2.02M | — | — | -$1.64M | -$1.17M | — | — | -$927,976 |
| Investing cash flow | -$72,830 | -$43,179 | -$49,345 | -$41,461 | -$40,151 | -$44,002 | -$78,288 | -$60,717 |
| Financing cash flow | -$6,325 | -$19,284 | $9.68M | $2.34M | -$283,798 | -$1 | $16.89M | $125,142 |
| Depreciation & amortization | $1,447 | $1,447 | $60,909 | $61,313 | $618 | $466 | $55,167 | $52,246 |
| Stock-based compensation | $424,821 | $102,117 | $4,694 | $4,365 | $16,746 | $28,360 | $55,897 | $56,618 |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.